- Home
- ELMD vs TGTX Comparison
ELMD vs TGTX Comparison
Compare ELMD & TGTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ELMD
- TGTX
- Stock Information
- Founded
- ELMD 1992
- TGTX 1993
- Country
- ELMD United States
- TGTX United States
- Employees
- ELMD N/A
- TGTX N/A
- Industry
- ELMD Biotechnology: Electromedical & Electrotherapeutic Apparatus
- TGTX Biotechnology: Pharmaceutical Preparations
- Sector
- ELMD Health Care
- TGTX Health Care
- Exchange
- ELMD Nasdaq
- TGTX Nasdaq
- Market Cap
- ELMD 206.5M
- TGTX 4.2B
- IPO Year
- ELMD 2010
- TGTX 1995
- Fundamental
- Price
- ELMD $24.32
- TGTX $31.99
- Analyst Decision
- ELMD Strong Buy
- TGTX Strong Buy
- Analyst Count
- ELMD 2
- TGTX 4
- Target Price
- ELMD $35.50
- TGTX $42.50
- AVG Volume (30 Days)
- ELMD 101.6K
- TGTX 2.0M
- Earning Date
- ELMD 11-11-2025
- TGTX 11-03-2025
- Dividend Yield
- ELMD N/A
- TGTX N/A
- EPS Growth
- ELMD 46.55
- TGTX N/A
- EPS
- ELMD 0.85
- TGTX 0.36
- Revenue
- ELMD $64,000,000.00
- TGTX $454,069,000.00
- Revenue This Year
- ELMD $14.47
- TGTX $82.58
- Revenue Next Year
- ELMD $10.33
- TGTX $44.99
- P/E Ratio
- ELMD $28.59
- TGTX $88.20
- Revenue Growth
- ELMD 16.97
- TGTX 30.96
- 52 Week Low
- ELMD $17.73
- TGTX $21.16
- 52 Week High
- ELMD $35.56
- TGTX $46.48
- Technical
- Relative Strength Index (RSI)
- ELMD 56.94
- TGTX 56.18
- Support Level
- ELMD $23.75
- TGTX $31.34
- Resistance Level
- ELMD $26.95
- TGTX $32.56
- Average True Range (ATR)
- ELMD 1.27
- TGTX 1.12
- MACD
- ELMD -0.05
- TGTX 0.38
- Stochastic Oscillator
- ELMD 32.78
- TGTX 72.94
About ELMD Electromed Inc.
Electromed Inc is a United States-based company that develops, manufactures, markets, and sells products that provide airway clearance therapy, including the SmartVest Airway Clearance System and related products, to patients with compromised pulmonary function with a commitment to excellence and compassionate service. The SmartVest System features a programmable air pulse generator, a therapy garment worn over the upper body and a connecting hose, which together provide safe, comfortable, and effective airway clearance therapy.
About TGTX TG Therapeutics Inc.
TG Therapeutics Inc is a fully integrated, commercial-stage, biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell diseases. The company has received approval from the U.S. Food and Drug Administration (FDA) for BRIUMVI (ublituximab-xiiy) for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS). In addition, it is developing TG-1701 (BTK inhibitor), Azer-Cel (allogeneic CD19 CAR T), and TG-1801 (anti-CD47/CD19 bispecific mAb) for B-cell disorders, which are under Phase 1 trials. Geographically, the company generates a majority of its revenue selling BRIUMVI in the United States, with the rest coming from sales in other countries.